First Targeted Bladder Cancer Treatment Shows Promising Phase I Results
Posted:
In a potential win for targeted therapy in bladder cancer, Johnson & Johnson announced results from a Phase I study of erdafitinib (Erda-iDRS) in patients with the intermediate-risk non-muscle-invasive form of the disease.
New York-based Claryx has emerged from stealth with $3.5 million in pre-seed funding.
Outlander VC led the round, with participation from Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford and Precursor Ventures.
The funding will help Claryx continue to "build…
Researchers have shown that measurements taken from a person's fingertip could help identify physical patterns associated with stress, anxiety and depression.
The international study, involving experts from Aston University, used a wearable device that shines light into the skin to…
Attendees
Sponsors and Exhibitors
Contact us